Diagnostic & Life Science Tools Companies
Supporting our diagnostic and life science tools clients as they reshape their businesses to be future leaders in Precision Medicine
A raft of innovative technologies such as liquid biopsy, multi-omic diagnostic tests, and cell and gene therapies are set to change treatment paradigms and drive better clinical outcomes for patients. This offers huge opportunities and challenges for diagnostic and life science tools companies, who must make important strategic choices in how they structure their businesses via divestiture, acquisition or partnership to ensure that they can meet the future needs of their markets. Whether it be strategic advice, or support across the deal lifecycle, KPMG is helping our diagnostics and life science tools clients position themselves for future leadership.
Example case studies
Assessing the commercial viability of an early-stage oncology diagnostics target
Download PDFIntegration support for a diagnostics provider following its first cross-border acquisition
Download PDFLiquid biopsy market assessment for a global diagnostic company
Download PDFExplore more
Insight
Hospitals, Healthcare Systems, and Labs
Delivering actionable strategic insights and deal support as our clients navigate the increasingly complex Precision Medicine ecosystem
Insight
Private Investors
Offering deal and non-deal services to our private investors as they look for opportunities in the Precision Medicine market
Insight
Biopharma Companies
Supporting the biopharma industry as it is develops and launches the most cutting edge innovation in Precision Medicine
KPMG in Precision Medicine
Meet our team
Subscribe to KPMG Healthcare and Life Sciences Insights
Industry insights and trends, one click away.